# EURTAC (NCT00446225)

> Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00446225
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Spanish Lung Cancer Group
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Erlotinib; Carboplatin; Gemcitabin; Docetaxel; Cisplatin
- Enrollment: 174
- Primary outcome: Progression Free-survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 9
- Podcasts: 2
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=eurtac-nct00446225

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00446225", "email": "<work email>"}; the inbox owner confirms by the emailed link.